Welcome to Psychiatryai.com: Latest Evidence - RAISR4D

Estimated reading time for CME/CPD: 2 mins

Resting State Functional Connectivity in Women With Depression Following Pregnenolone Administration

AI Summary
  • Pregnenolone 500 mg/day significantly decreased bilateral amygdala to left frontal pole resting connectivity compared with placebo (PFDR = .011).
  • No significant amygdala connectivity change occurred with 800 mg/day, suggesting an inverted-U dose response where moderate dosing is optimal.
  • Both pregnenolone doses significantly increased serum allopregnanolone; rsfMRI analyses used a per-protocol female sample of 11 within a crossover design.
Summarise with AI (MRCPsych/FRANZCP)

J Clin Psychiatry. 2026 Nov 18;87(4):26m16360. doi: 10.4088/JCP.26m16360.

ABSTRACT

Background: Neurosteroids, such as pregnenolone, have potential in mood disorder treatment. Because depression is associated with dysregulated connectivity in brain networks, a systems-level biomarker for neurosteroids modulation of large-scale brain networks can offer critical insight into circuits underlying treatment response. To our knowledge, no studies have examined resting-state functional connectivity (rsFC) in people with depression following pregnenolone administration.

Methods: In this crossover design study conducted between 2019-2021, women (n=29, mean age=45.6 years) with major depressive disorder (DSM-5) were randomized to 7 days of oral pregnenolone 500 mg/d, pregnenolone 800 mg/d, and placebo with a 14-day washout between conditions. After each treatment, steroid levels and resting-state fMRI (rsfMRI) data were collected. A seed-based voxel-wise analysis, with bilateral amygdala as seed, investigated rsFC alterations following treatment conditions in a per-protocol sample (n=11).

Results: Compared to placebo, pregnenolone 500 mg/d was associated with decreased connectivity between the bilateral amygdala and left frontal pole (PFDR=.011). Difference in amygdala connectivity between pregnenolone 800 mg/d and placebo was nonsignificant. Allopregnanolone serum levels increased significantly with administration of either pregnenolone dose as compared to placebo.

Conclusions: Findings suggest that pregnenolone 500 mg/d was associated with decreased connectivity between the amygdala and frontal pole, brain regions pertinent to depression and cognitive control. Presence of rsFC changes at 500 mg/d but not 800 mg/d suggests an inverted-U dose-response pattern, where moderate dosing optimally engages neural circuits compared to higher doses.

Trial Registration: ClinicalTrials.gov identifier: NCT03645096.

PMID:43055647 | DOI:10.4088/JCP.26m16360

Document this CPD

Share Evidence Blueprint

QR Code

Save to Google Notes

Search Google Scholar

⭐ My Revision List

close chatgpt icon
ChatGPT

Enter your request.

← →
RAISR4D CME/CPD Evidence Nodes
Swipe to navigate RAISR4D CME/CPD evidence nodes.
CME/CPD